MRC Puts £50 Million Behind New UK Push on Mitochondrial Disease

The Medical Research Council has invested £50 million in a new centre focused on mitochondrial disease, in a move aimed at improving treatment options for a group of genetic disorders that currently has no cure.

Why the new centre matters

Announced on 5 August 2026, the MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics will bring together experts from different disciplines to study how mutations in mitochondrial DNA cause disease and to translate that knowledge into therapies. The MRC says the conditions affect around one in 5,000 people and create significant unmet medical needs for patients and families.

The centre will also examine broader links between mitochondrial DNA mutations and serious health problems, including neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration. According to the MRC, mitochondrial dysfunction can lead to severe disability, progressive decline and premature death.

What the researchers plan to do

Led by the University of Cambridge, the programme will collaborate with the University of Birmingham, The University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. It will also work with the Lily Foundation and industry partners worldwide. The MRC says the centre will use emerging technologies to engineer the mitochondrial genome and create advanced models of pathogenic mtDNA mutations.

Professor Michal Minczuk, the project lead, said the centre will build a long-term UK research platform with the scale, expertise and infrastructure needed to position the country as a global leader in mitochondrial genome therapeutics. Dr Ceri Williams of the MRC said the initiative builds on the UK’s earlier work on mitochondrial replacement therapy and could improve prevention, detection and treatment.

Patient groups and long-term impact

The Lily Foundation, which is named as a partner in the initiative, said the project has the potential to transform understanding of mitochondrial disease and should embed patient perspectives from the outset. The charity also said it will help ensure that family priorities shape the research while supporting the next generation of scientists.

For researchers and clinicians, the new investment signals continued momentum behind rare disease science in the UK, with the goal of turning basic discoveries into practical therapies for patients who currently have few treatment options.

Read the MRC announcement

Photo source: AI-generated or edited image iThis image was created or edited using AI based on the article summary and may not depict a real photographed moment.